Next Article in Journal
Dynamic Changes in Anthocyanin Accumulation and Cellular Antioxidant Activities in Two Varieties of Grape Berries during Fruit Maturation under Different Climates
Previous Article in Journal
Chemical Profile, Antimicrobial and Antioxidant Activity Assessment of the Crude Extract and Its Main Flavonoids from Tartary Buckwheat Sprouts

Aptamers: Potential Diagnostic and Therapeutic Agents for Blood Diseases

Institute of Physical Chemistry and Abbe Center of Photonics, Friedrich Schiller University, Helmholtzweg 4, 07743 Jena, Germany
Department of Pathology, College of Medicine, Taibah University, Madinah 42353, Saudi Arabia
Leibniz Institute of Photonic Technology, Albert-Einstein-Str. 9, 07745 Jena, Germany
Center for Applied Research, InfectoGnostics Research Campus Jena, University of Jena, Philosophenweg 7, 07743 Jena, Germany
Department of Chemistry, Alfaisal University, Riyadh 11533, Saudi Arabia
College of Medicine, Alfaisal University, Al Zahrawi Street, Al Maather, Al Takhassusi Rd, Riyadh 11533, Saudi Arabia
Authors to whom correspondence should be addressed.
Academic Editor: Nicola Borbone
Molecules 2022, 27(2), 383;
Received: 5 November 2021 / Revised: 15 December 2021 / Accepted: 4 January 2022 / Published: 7 January 2022
Aptamers are RNA/DNA oligonucleotide molecules that specifically bind to a targeted complementary molecule. As potential recognition elements with promising diagnostic and therapeutic applications, aptamers, such as monoclonal antibodies, could provide many treatment and diagnostic options for blood diseases. Aptamers present several superior features over antibodies, including a simple in vitro selection and production, ease of modification and conjugation, high stability, and low immunogenicity. Emerging as promising alternatives to antibodies, aptamers could overcome the present limitations of monoclonal antibody therapy to provide novel diagnostic, therapeutic, and preventive treatments for blood diseases. Researchers in several biomedical areas, such as biomarker detection, diagnosis, imaging, and targeted therapy, have widely investigated aptamers, and several aptamers have been developed over the past two decades. One of these is the pegaptanib sodium injection, an aptamer-based therapeutic that functions as an anti-angiogenic medicine, and it is the first aptamer approved by the U.S. Food and Drug Administration (FDA) for therapeutic use. Several other aptamers are now in clinical trials. In this review, we highlight the current state of aptamers in the clinical trial program and introduce some promising aptamers currently in pre-clinical development for blood diseases. View Full-Text
Keywords: aptamers; diagnostic; therapeutic; blood diseases aptamers; diagnostic; therapeutic; blood diseases
Show Figures

Figure 1

MDPI and ACS Style

Aljohani, M.M.; Cialla-May, D.; Popp, J.; Chinnappan, R.; Al-Kattan, K.; Zourob, M. Aptamers: Potential Diagnostic and Therapeutic Agents for Blood Diseases. Molecules 2022, 27, 383.

AMA Style

Aljohani MM, Cialla-May D, Popp J, Chinnappan R, Al-Kattan K, Zourob M. Aptamers: Potential Diagnostic and Therapeutic Agents for Blood Diseases. Molecules. 2022; 27(2):383.

Chicago/Turabian Style

Aljohani, Maher M., Dana Cialla-May, Jürgen Popp, Raja Chinnappan, Khaled Al-Kattan, and Mohammed Zourob. 2022. "Aptamers: Potential Diagnostic and Therapeutic Agents for Blood Diseases" Molecules 27, no. 2: 383.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop